-

Bayer Partners with America’s Grow-A-Row to Aid in the Fight Against Hunger in New Jersey

Bayer employees live out their mission by harvesting 156,000 pounds of locally grown, fresh produce to provide nutrition to families facing food insecurity

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced the successful completion of its fall employee engagement campaign with America’s Grow-a-Row (AGAR), a New Jersey-based, nonprofit farm where approximately 300 employees harvested 156,000 pounds of corn and turnips. This four-day effort hand-collected the produce, which was donated to local food banks, resulting in an estimated 628,000 meals to families in need.

Bayer’s partnership with AGAR and over 190 other food banks, pantries, and organizations across the U.S., ensures that families across America have access to the healthy, nutritious foods they need to take care of themselves. In New Jersey alone, nearly one million people struggle with food insecurity.

“One way we work to achieve our mission ‘Health for all, Hunger for none’ is by giving back to the communities where we live and work. Access to nutritious foods and fresh produce are key to healthy communities,” said Michael Sullivan, Senior VP of Product Supply, Bayer North America. “It is through our collective efforts that we can truly advance our mission and create a healthier future for all.”

In 2024, AGAR aims to donate 3.6 million pounds, or 14.4 million servings, of fresh produce, and Bayer is proud to play a role to fulfill this goal. Bayer’s initiative included four volunteer days, which brought together employees from its New Jersey sites in Whippany and Morristown, as well as our Pennsylvania-based employees in Myerstown and Manchester.

"We are incredibly grateful for our longstanding partnership with Bayer and the dedicated Team Bayer volunteers who once again have come together to make a significant impact in our communities. Together we are filling hearts and filling bellies across the areas in which we serve, through promoting healthy living,” said Chip Paillex, President and Founder of America’s Grow-a-Row. “Eating healthy should not be a luxury and it’s inspiring to see organizations like Bayer so committed from both a physical and financial standpoint to help ensure that every family has access to the healthy food they deserve."

In addition to its partnership with AGAR, Bayer has maintained a long-standing partnership with country music star, Luke Bryan, to address food insecurity and improve access to health and nutrition. This year, as part of the ‘Take Care, Now’ campaign, the partners donated one million meals to the Feeding America network of food banks and food pantries in rural communities, bringing the total to more than 9 million meals since the partnership began in 2015. In addition, 100,000 bottles of One A Day® and Flintstones® Multivitamins were donated, along with other nutritional supplements, nutrition education toolkits, and healthy recipe guides.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros.

About America’s Grow-a-Row

America’s Grow-a-Row is a nonprofit farm located in Hunterdon County, New Jersey that grows and rescues fresh, healthy fruits and vegetables that are then donated to hunger relief agencies throughout New Jersey, New York City, Philadelphia, and beyond. Through Free Farm Markets and partnerships with food banks, they donate to every county in NJ. Key to their mission is educating people of all ages about nutrition and healthy eating to give people facing hunger the confidence to prepare healthy meals for their families while on a tight budget.

Social Media Channels

- Facebook: BayerUnitedStates

- Instagram: BayerUS

- YouTube: BayerUS

- X: BayerUS

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Contacts

Bayer
Nicole Hayes
Nicole.Hayes@Bayer.com

America’s Grow-a-Row
Jackie Etter
Jackie@americasgrowarow.org

Bayer


Release Versions

Contacts

Bayer
Nicole Hayes
Nicole.Hayes@Bayer.com

America’s Grow-a-Row
Jackie Etter
Jackie@americasgrowarow.org

More News From Bayer

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, placebo-controlled, group-comparison trial (NCT07211685), with an extension phase, which will investigat...

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic resonance imaging (MRI) at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a dose reduction...

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women. NAEH is an abnormal thickening of the lining of the uterus, known as the endometrium, due to an imbalance between estrogen and progesterone levels. This condition is classified as nonatypical as the cells...
Back to Newsroom